Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (55 quarters reported)
$34.2M in Q4 2012 → $80.9M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Replimune Group Inc. | 100.0% | New | 7,310,656 | $80.9M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Replimune Group Inc. | New | +7,310,656 | +$80.9M | 100.0% |
| 0 0 | Exited | +0 | — | — |
quarter ended March 31, 2026 · filed May 15, 2026
No position changes this quarter.
quarter ended December 31, 2025 · filed February 17, 2026
No position changes this quarter.
quarter ended September 30, 2025 · filed November 14, 2025
No position changes this quarter.
quarter ended June 30, 2025 · filed August 14, 2025
No position changes this quarter.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Pyxis Oncology Inc | Exited | −359,231 | −$560K | — |
| 0 0 | New | +0 | — | — |
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Pyxis Oncology Inc | New | +359,231 | +$560K | 100.0% |
| 0 0 | Exited | +0 | — | — |
quarter ended September 30, 2024 · filed November 14, 2024
No position changes this quarter.
Loading...
